


The goal of the COVER-MS study is to learn about the effects of the COVID-19 vaccines in people with MS. This is a snapshot of our findings about the vaccination side effects and reactions experienced by our participants.

Main finding: The frequency of vaccination reactions reported in COVER-MS was **very similar to** that reported in the COVID-19 vaccine clinical trials.



Vaccine Received	%
Pfizer-BioNTech	57%
Moderna	36%
J&J	4%
Oxford/AstraZeneca	3%
Other	<1%

Which COVER-MS participants were more likely to experience reactions?


- Younger people
- Women
- Those with a prior COVID-19 infection
- Those who had a reaction after the 1st shot

What factors did not correlate with reactions?

- Whether someone was on a disease-modifying therapy or not
- Participants' type of MS or how long they had had MS


Participants included in this analysis: 719

Sex



MS Type	%
RRMS	70%
SPMS	18%
PPMS	9%
CIS/RIS	2%

MS Disease-modifying therapies used



Average age: 53 years ♦ Race: White 94%, All others 6% ♦ Ethnicity: Latinx 5%, Non-Latinx 95%